UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Multi-institutional evaluation of the reproducibility and the accuracy of the objective breast cosmesis scale

Brachytherapy, 2018-11, Vol.17 (6), p.944-948

2018

Volltextzugriff (PDF)

Bildung und Elimination von Verdoglobinen

Naunyn-Schmiedeberg's archives of pharmacology, 1943-11, Vol.200 (6), p.648-683

1943

Volltextzugriff (PDF)

FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial

British journal of cancer, 2021-02, Vol.124 (3), p.587-594

2021

Volltextzugriff (PDF)

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

The lancet oncology, 2014-09, Vol.15 (10), p.1065-1075

2014

Volltextzugriff (PDF)

Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer

Journal of clinical oncology, 2015-11, Vol.33 (32), p.3718-3726

2015

Volltextzugriff (PDF)

Relation of early tumor shrinkage (ETS) observed in first‐line treatment to efficacy parameters of subsequent treatment in FIRE‐3 (AIOKRK0306)

International journal of cancer, 2017-04, Vol.140 (8), p.1918-1925

2017

Volltextzugriff (PDF)

Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity

Proceedings of the National Academy of Sciences - PNAS, 2021-01, Vol.118 (1), p.1-12

2021

Volltextzugriff (PDF)

Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306)

Oncotarget, 2017-12, Vol.8 (62), p.105749-105760

2017

Volltextzugriff (PDF)

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

Clinical lymphoma, myeloma and leukemia, 2018-10, Vol.18 (10), p.e401-e419

2018

Volltextzugriff (PDF)

Prognostic importance of primary tumor resection and synchronous metastasis on overall survival in metastatic colorectal cancer: Data from the FIRE-3 (AIO KRK-0306) study

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.4070-4070

2020

Volltextzugriff (PDF)

Effect of patient age on efficacy of FOLFIRI plus cetuximab vs bevacizumab in 1st-line treatment of metastatic colorectal cancer: An analysis of FIRE-3 (AIO KRK 0306)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.3541-3541

2019

Volltextzugriff (PDF)

Per protocol analysis and final OS update of the FIRE-3 (AIO KRK-0306) study comparing FOLFIRI plus cetuximab vs. FOLFIRI plus bevacizumab

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.3508-3508

2018

Volltextzugriff (PDF)

Primary tumor location and efficacy of second-line therapy after initial treatment with FOLFIRI in combination with cetuximab or bevacizumab in patients with metastatic colorectal cancer- FIRE-3 (AIOKRK0306)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.3525-3525

2017

Volltextzugriff (PDF)

Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3)

Journal of clinical oncology, 2013-06, Vol.31 (18_suppl), p.LBA3506-LBA3506

2013

Volltextzugriff (PDF)

Time-course evaluation of survival and treatment in FIRE-3 trial (AIO KRK0306)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.3528-3528

2016

Volltextzugriff (PDF)

Time-course evaluation of survival and treatment in FIRE-3 (AIO KRK0306, first-line therapy of KRAS wild-type metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab)

Journal of clinical oncology, 2016-02, Vol.34 (4_suppl), p.617-617

2016

Volltextzugriff (PDF)

Treatment until progression: Data of the “on-treatment” population of the FIRE-3 (AIO KRK-0306) study

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.3589-3589

2015

Volltextzugriff (PDF)

Second-line therapies in patients with KRAS wild-type metastatic colorectal cancer (mCRC) after first-line therapy with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK0306 (FIRE 3) trial

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.3558-3558

2014

Volltextzugriff (PDF)

Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.3600-3600

2014

Volltextzugriff (PDF)

AIO KRK0306, FIRE3 trial: CEA and CA19-9 influence outcome of patients with KRAS exon wild-type metastatic colorectal cancer (mCRC) receiving first-line therapy with FOLFIRI plus cetuximab or bevacizumab

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.3592-3592

2014

Volltextzugriff (PDF)

Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.LBA3506-LBA3506

2013

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(26)

Sprache

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Multi-institutional evaluation of the reproducibility and the accuracy of the objective breast cosmesis scale

Bildung und Elimination von Verdoglobinen

FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial

Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer

Relation of early tumor shrinkage (ETS) observed in first‐line treatment to efficacy parameters of subsequent treatment in FIRE‐3 (AIOKRK0306)

Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity

Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3

Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306)

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

Prognostic importance of primary tumor resection and synchronous metastasis on overall survival in metastatic colorectal cancer: Data from the FIRE-3 (AIO KRK-0306) study

Effect of patient age on efficacy of FOLFIRI plus cetuximab vs bevacizumab in 1st-line treatment of metastatic colorectal cancer: An analysis of FIRE-3 (AIO KRK 0306)

Per protocol analysis and final OS update of the FIRE-3 (AIO KRK-0306) study comparing FOLFIRI plus cetuximab vs. FOLFIRI plus bevacizumab

Primary tumor location and efficacy of second-line therapy after initial treatment with FOLFIRI in combination with cetuximab or bevacizumab in patients with metastatic colorectal cancer- FIRE-3 (AIOKRK0306)

Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3)

Time-course evaluation of survival and treatment in FIRE-3 trial (AIO KRK0306)

Time-course evaluation of survival and treatment in FIRE-3 (AIO KRK0306, first-line therapy of KRAS wild-type metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab)

Treatment until progression: Data of the “on-treatment” population of the FIRE-3 (AIO KRK-0306) study

Baseline carcinoembryonic antigen (CEA) serum levels to predict bevacizumab-based treatment response in patients with KRAS exon wild-type metastatic colorectal cancer (mCRC) receiving 1st-line therapy with FOLFIRI plus cetuximab or bevacizumab (AIO KRK0306, FIRE3 trial)

Influence of adjuvant pretreatment on outcome of FIRE-3 (AIO KRK-0306): A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients

Second-line therapies in patients with KRAS wild-type metastatic colorectal cancer (mCRC) after first-line therapy with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK0306 (FIRE 3) trial

Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial

AIO KRK0306, FIRE3 trial: CEA and CA19-9 influence outcome of patients with KRAS exon wild-type metastatic colorectal cancer (mCRC) receiving first-line therapy with FOLFIRI plus cetuximab or bevacizumab

Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3)

Suchergebnisse filtern